CARL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Carlsmed Inc (CARL) is not a strong buy at this moment for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The technical indicators are bearish, there are no recent positive news catalysts, and the financial performance shows weak growth trends. While analysts maintain a Buy rating with an increased price target, the lack of strong trading signals and the company's current financial struggles suggest holding off on investing right now.
The technical indicators for CARL are bearish. The MACD histogram is negative and contracting, RSI is neutral at 21.785, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support is at 9.995, and resistance is at 11.744. The stock has a 60% chance of declining by -2.26% in the next day, with minimal upside potential in the short term.
Analysts from Goldman Sachs and Deutsche Bank have raised price targets and maintained Buy ratings, indicating confidence in the stock's long-term potential. Gross margin increased by 3.71% YoY to 76.54%.
The stock's financial performance is weak, with revenue stagnant (0.00% YoY growth), net income still negative (-$8.61M), and EPS declining significantly (-65.96% YoY). Technical indicators are bearish, and there are no recent news or significant trading trends to support a positive outlook.
In Q4 2025, revenue remained flat at $15.165M (0.00% YoY growth), net income was -$8.61M (unchanged YoY), and EPS dropped by -65.96% YoY to -0.32. Gross margin improved slightly to 76.54%, up 3.71% YoY, but overall financial performance remains weak.
Goldman Sachs raised the price target to $20 from $19 with a Buy rating, citing a return to normalized growth patterns in 2026. Deutsche Bank also raised the price target for Carlsberg (unrelated to Carlsmed) but maintained a Buy rating. Analysts are optimistic about the stock's long-term potential despite current challenges.
